Objective: The aim was to assess the status of estrogen and progesterone receptors, p53 and MIB-1 labeling in invasive duct carcinomas in our institute. Study design: A series of 63 invasive duct carcinomas occurring in women for consecutive five years were studied at our institute. Subjects and methods: In this study 63 cases of invasive duct carcinoma, including all the histological subtypes were reviewed with original archival data including histological type of tumour and tumour grade. Tumour blocks of each case were retrieved for immunohistochemical staining of estrogen and progesterone receptors, MIB-1 and p53. The expression was studied using established protocols. The majority of the cases were above 30 years of age and postmenopausal. In total 77.8% had node positive disease with 71% having nodes greater than 2 cm. Estrogen and progesterone (ER and PR) receptor positivity was seen in 32.5% and 28.5% respectively. According to the percentage of nuclear staining, 60.3% of the cases were p53 positive and 77.7% showed proliferation activity as seen by MIB-1 labeling. The cases were analysed after following up with survival data. Conclusion: P53 and MIB-1 are independent indicators of aggressiveness and grade of the tumors. They have the potential to replace SBR grading of breast cancer.

Keywords: Immunohistochemistry; Breast carcinoma; MIB-1 labeling index.